Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Other Neutral

Appili Therapeutics to Exhibit at World Vaccine Congress Washington

Appili Touts Non-Dilutive Grants as Cash Burn Outpaces Micro-Cap Equity Raises

By The Northwire Desk — AI Analysis Mar 30, 2026 · 07:19 APLI · 0.02 APPILI THERAPEUTICS INC. J
Executive Summary
  • Appili Therapeutics announced its exhibition at the World Vaccine Congress Washington (March 31 – April 2, 2026) to network with government agencies, vaccine experts, and potential collaborators.
  • The release highlights a previously announced US$40 million NIAID contract for the VXV-01 fungal vaccine and introduces a US$11.7 million U.S. Air Force Academy award for the ATI-1701 tularemia vaccine.
  • Management provided brief updates on commercial product LIKMEZ (recently relaunched in the U.S.) and ATI-1801 (Phase 3 efficacy demonstrated for leishmaniasis).
  • The stated objective is to leverage the conference to secure additional non-dilutive government funding and advance partnership discussions.
Material Impact
  • The announcement is promotional and recycles funding figures already disclosed in late 2025. The US$11.7 million Air Force award is newly highlighted but represents milestone-based government funding, not immediate cash.
  • No new clinical data, regulatory approvals, commercial revenue milestones, or binding partnership agreements were announced.
  • Given the company’s micro-cap valuation and historically low cash balance, a conference attendance notice does not alter the fundamental liquidity position or near-term operational trajectory.
  • The market has already priced in the US$40 million NIAID award, as evidenced by the stock’s return to its pre-announcement trading range.
APLI · Price
Company Overview
  • Appili Therapeutics is a clinical-stage biotechnology company focused on developing vaccines and therapeutics for infectious diseases and biodefense.
  • Flagship project: VXV-01, a dual-antigen vaccine targeting invasive fungal infections (Candida albicans, C. auris), backed by a US$40 million NIAID contract covering IND-enabling work and Phase 1 trials.
  • Secondary pipeline includes ATI-1701 (tularemia vaccine), ATI-1801 (topical paromomycin for cutaneous leishmaniasis), and LIKMEZ (commercialized oral metronidazole suspension generating royalties and milestone payments).
Read the original news release →

More from APPILI THERAPEUTICS INC. J

Jun 26, 2026 · 18:29

Pre-revenue biotech burns through cash, relies on distant government milestones while facing immediate going-concern liquidity crunch.

Earnings Feb 18, 2026 · 07:19

Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement

Financings Feb 12, 2026 · 18:15

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026

Earnings Dec 18, 2025 · 18:34

Appili closes $177,500 first tranche of placement

Financings Dec 18, 2025 · 07:31

Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

Financings Nov 13, 2025 · 17:21

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026

Production / Operations